Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
[forminator_form id="25163"]
All voices matter
Novartis signs $3.2B deal for Alteogen’s injection technology
- Novartis signed a licensing deal worth up to $3.22 billion with South Korea's Alteogen for its Hybrozyme drug delivery technology.
reuters - The ALT-B4 platform converts IV infusions into under-the-skin injections; the same tech powers Merck's FDA-approved Keytruda Qlex.
finance.yahoo - The deal is Alteogen's fourth such licensing agreement this year, reflecting surging industry demand for subcutaneous drug formulations.
reuters+1
Novartis announced Wednesday it has signed a licensing and option agreement with South Korean biotech Alteogen worth up to $3.22 billion, gaining access to technology that converts intravenous drugs into simpler under-the-skin injections.reuters
The deal gives Novartis multiple options to secure exclusive rights to Alteogen's Hybrozyme platform and its ALT-B4 enzyme, known as berahyaluronidase alfa. The total value includes option exercise fees, milestone payments, and royalties on future product sales, payable if Novartis exercises all options and all development and commercial milestones are met.koreajoongangdaily+1
How the Technology Works
ALT-B4 works by temporarily breaking down hyaluronan, a natural substance in the body's tissue, allowing medicines to spread and absorb more quickly when injected under the skin. The approach enables biologic drugs currently administered through time-consuming IV infusions to be reformulated as subcutaneous injections — a shift that shortens treatment times and could improve patient adherence.ad-hoc-news+1
The technology has already proven its commercial value. ALT-B4 is used in the injectable version of Merck's top-selling cancer drug Keytruda, branded as Keytruda Qlex, which received FDA approval last year. The Novartis agreement marks Alteogen's fourth ALT-B4 licensing deal with a global pharmaceutical company this year.finance.yahoo+1
A Busy Week for Novartis
The Alteogen pact arrives during a dense stretch of news for the Basel-based drugmaker. Days earlier, Novartis reported positive Phase III results for remibrutinib in relapsing multiple sclerosis, with the BTK inhibitor reducing annualized relapse rates compared with teriflunomide in two trials. Global regulatory submissions are now being prepared, with full data set for presentation at the MSToronto2026 congress in October.ad-hoc-news
On August 24, however, Novartis suspended eight clinical trials of its experimental CAR-T cell therapy rap-cabtagene autoleucel following three patient deaths linked to severe immune reactions. The halt affects autoimmune and neurology indications only, with oncology studies continuing, according to Reuters.ad-hoc-news
Broader Context
The deal reflects a wider industry trend toward subcutaneous formulations. Novartis shares rose as much as 5.6 percent in early Zurich trading this week, with investors weighing the remibrutinib data and the Alteogen partnership as more consequential than the CAR-T setback. The company is scheduled to participate in a fireside chat at the Jefferies healthcare conference on September 3.ad-hoc-news
Sources (4)
- 1 Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology www.reuters.com
- 2 Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology finance.yahoo.com
- 3 Alteogen signs deal with Novartis worth up to 4.4 trillion won for subcutaneous formulations www.koreajoongangdaily.com
- 4 Novartis Piles Up a Week of Contrasts: A Licensing Bet, Promising MS Data, and a Clinical Setback www.ad-hoc-news.de
